Long-Lasting Benefit Observed With Atezolizumab and Bevacizumab in Recurrent Endometrial Cancer
October 03, 2022

Results from a phase 2 trial indicated that atezolizumab and bevacizumab yielded a significant duration of response in recurrent endometrial cancer.

Additional Studies Needed for Immunotherapy Combinations in Clear Cell Ovarian Carcinoma
October 03, 2022

Despite inconclusive efficacy results regarding the use of pembrolizumab plus epacadostat in patients with recurrent clear cell ovarian carcinoma, rapid accrual to the trial reveals an unmet need in this cancer subset.

Phase 3 TRITON3 Trial Meets Primary End Point of Radiographic PFS With Rucaparib for mCRPC
October 03, 2022

Results from the phase 3 TRITON3 trial demonstrated that radiographic progression-free survival was significantly improved when patients with metastatic castration-resistant prostate cancer were treated with rucaparib monotherapy vs physician’s choice.

Increased Atrial Fibrillation/Stroke Risk Did Not Impact TTD/TTNT Outcomes Associated with Ibrutinib for CLL/SLL
October 03, 2022

A real-world study found that time to discontinuation and time to next treatment outcomes associated with ibrutinib were not impacted by a baseline high risk of atrial fibrillation or stroke in patients with chronic lymphocytic leukemia or small cell lymphocytic lymphoma.

PSA Levels at 8 Months Predict Survival Outcomes With ADT Combinations in mCRPC
October 03, 2022

A recent analysis of data from the phase 3 PEACE-1 study reveals a correlation between 8-month prostate-specific antigen levels and survival outcomes in patients with metastatic castration-sensitive prostate cancer who are treated with systemic therapy regimens that include androgen deprivation therapy.

FDA Approves Bevacizumab-adcd Biosimilar in 6 Cancer Types
October 02, 2022

Based on results from a phase 3 trial, a bevacizumab biosimilar, bevacizumab-adcd, was approved by the FDA for patients with metastatic or recurrent non-squamous non–small cell lung in addition to 5 other disease types.

Pembrolizumab Granted 4 Approvals in Japan for High-Risk TNBC, RCC, and More
October 02, 2022

Japan’s Ministry of Health, Labor and Welfare approved pembrolizumab for use in 4 indications, including high-risk, early-stage triple-negative breast cancer, stage IIB or IIC melanoma, adjuvant renal cell carcinoma, and recurrent/metastatic cervical cancer.

David O’Malley, MD, Discusses PFS Benefit of Maintenance Rucaparib Regardless of Surgery Outcome in Newly Diagnosed Ovarian Cancer
October 01, 2022

Data from the phase 3 ATHENA-MONO study indicated that maintenance rucaparib yielded progression-free survival benefit vs placebo across all subgroups in a population of patients newly diagnosed ovarian cancer, according to David O’Malley, MD.

Early Data Show Clinical Benefit With Gavocabtagene Autoleucel in Advanced Solid Tumors
October 01, 2022

Treatment with gavocabtagene autoleucel demonstrated efficacy and tolerability in patients with mesothelin-expressing solid tumors, according to updated data from an ongoing phase 1/2 clinical trial.

FDA Grants Accelerated Approval to Futibatinib in FGFR2+ Locally Advanced/Metastatic Intrahepatic Cholangiocarcinoma
September 30, 2022

Results from the phase 1/2 TAS-120-101 trial lead to the accelerated approval of futibatinib in patients with locally advanced or metastatic cholangiocarcinoma and an FGFR2 gene fusion or rearrangement.